<?xml version="1.0" encoding="UTF-8"?>
<p>Ivermectin is an FDA-approved broad spectrum anti-parasitic agent mainly used in the treatment of onchocerciasis, which shows anti-viral effects against HIV-1, simian virus SV40, dengue virus (DENV), West Nile Virus, Venezuelan equine encephalitis virus (VEEV) and Influenza virus [
 <xref rid="B166-ijms-21-05559" ref-type="bibr">166</xref>]. Ivermectin inhibits the interaction between the integrase protein (IN) of HIV-1 and importin (IMP) α/β1 heterodimer that is responsible for IN nuclear import [
 <xref rid="B167-ijms-21-05559" ref-type="bibr">167</xref>]. Due to the important role of nuclear transport of viral proteins in the replication cycle as well as inhibition of the host antiviral response, targeting this step might be a therapeutic approach [
 <xref rid="B168-ijms-21-05559" ref-type="bibr">168</xref>]. Recently, a study on Vero-hSLAM cell lines infected with SARS-CoV-2 has shown that ivermectin can reduce viral RNA up to 5000-fold, equal to a 99.98% reduction after 48 h [
 <xref rid="B166-ijms-21-05559" ref-type="bibr">166</xref>]. Momekov et al. using available pharmacokinetic data from ivermectin showed that its inhibitory concentrations against the SARS-CoV-2 is unlikely attainable in humans [
 <xref rid="B169-ijms-21-05559" ref-type="bibr">169</xref>]. Overall, the possible efficacy of ivermectin against SARS-CoV-2 infection needs data to support it.
</p>
